• Users Online: 316
  • Print this page
  • Email this page
 
ORIGINAL ARTICLE
Ahead of Print

Combined intravitreal ranibizumab and posterior subtenon triamcinolone acetonide injections for patients with diabetic macular edema refractory to intravitreal ranibizumab monotherapy


1 Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City, Chine, Taiwan
2 Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City; Department of Electrical Engineering, Yuan Ze University, Taoyuan City, Taiwan
3 Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City; Department of Medicine, National Taiwan University, New Taipei City, Taiwan
4 Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City; Department of Electrical Engineering, Yuan Ze University, Taoyuan City; Department of Medicine, National Taiwan University, New Taipei City, Taiwan; Department of Medicine, National Yang Ming University, New Taipei City; Department of Healthcare Administration, Oriental Institute of Technology, New Taipei City; Department of Nursing, Oriental Institute of Technology, New Taipei City, Taiwan

Correspondence Address:
Jia-Kang Wang,
Department of Ophthalmology, Far Eastern Memorial Hospital, No. 21, Sec. 2, Nan-Ya South Road, Pan-Chiao District, New Taipei City 220
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/tjo.tjo_31_20

PURPOSE: The purpose of this study is to compare the efficacy of intravitreal ranibizumab (IVR) alone and concurrent IVR with posterior subtenon triamcinolone acetonide (PSTA) injection for patients with diabetic macular edema (DME) refractory to IVR monotherapy. MATERIALS AND METHODS: We enrolled 43 eyes of 43 patients with DME who received at least three times of IVR, which resulted in poor anatomical responses, with central foveal thickness (CFT) reduction <10% and postinjection CFT >300 mm. All the eyes received initial 3 monthly then pro re nata (PRN) IVR 0.5 mg injections. Twenty eyes continued PRN injections and 23 eyes received combined IVR 0.5 mg and PSTA 40 mg with at least 1 year follow up. Best corrected visual acuity (BCVA) and CFT were recorded from 1 month to 1 year follow up. RESULTS: Following switch to combined therapy, the mean BCVA significantly improved from 0.61 ± 0.32 logarithm of the minimum angle of resolution (logMAR) to 0.45±0.39 logMAR at 6 month (P = 0.003), 0.43±0.35 logMAR at 9 months (P < 0.001), and 0.48±0.45 logMAR at 1 year (P = 0.03). In eyes with IVR alone, no significant VA improvement was noted throughout the year. Significantly better BCVA was noted in the combined group at 6 month, 9 month, and 1 year follow up compared to IVR alone group. The timing of combined therapy showed a significant association with 1 year BCVA (t = 3.25, P = 0.018). CONCLUSION: Concurrent IVR and PSTA resulted in significantly better visual outcomes in 1 year follow up for those refractory to preceding ranibizumab monotherapy for DME. Early addition of PSTA predicted a better visual outcome.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Chiu CY
    -  Huang TL
    -  Chang PY
    -  Chen FT
    -  Hsu YR
    -  Chen YJ
    -  Wang JK
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed111    
    PDF Downloaded3    

Recommend this journal